completed

The objective of the DREAM study was to evaluate whether ramipril and/or rosiglitazone prevent the onset of type 2 diabetes in people with prediabetes and without cardiovascular disease.

The trial found no clear benefit for ramipril and a large reduction in incident diabetes with rosiglitazone. Ramipril did not reduce the incidence of CV and renal events; Rosiglitazone reduced the incidence of renal events, had an overall neutral effect on CV events and increased the incidence of heart failure. Based on the trial results rosiglitazone is suggested as a possible therapy to reduce the risk for diabetes in some countries.

Primary endpoint:

Composite newly diagnosed diabetes or death.

Secondary endpoints:

Composite of CV events
Myocardial infarction (MI)
Stroke
Congestive heart failure
Angina
Revascularization procedures
Ventricular arrhythmia
Renal events

All primary and secondary outcomes were adjudicated.

Study Type

Interventional - Drug

Study Design

Randomized, double-blind, placebo control, factorial assignment, efficacy study

NO. of Countries

21

NO. of Sites

191

NO. of Participants

5269

Study Period

2002-2006

Sponsor

PHRI

Back To Top